Ulcerative Colitis

In March 2020, there was so much we did not know about COVID-19 and how it would impact the world of gastroenterology. Were our patients at risk? How long would endoscopy be disrupted? When will things be normal again?

Fecal dipeptidyl peptidase-4 may be used as a noninvasive biomarker in patients with inflammatory bowel disease, according to research published in Clinical and Translational Gastroenterology.

Simultaneous use of biologic agents in combination or with Xeljanz may be a viable treatment option for highly selected, refractory patients with inflammatory bowel disease, according to study results.

These reports include new research on the impact of greenspace exposure, gluten intake and yeast commonly found in cheese.

Dietary gluten intake was not associated with risk for Crohn’s disease or ulcerative colitis, according to study results.

Monogenic inflammatory bowel disease, while rare, has varied extra-intestinal comorbidities and limited treatments, according to a study published in Clinical Gastroenterology and Hepatology.

Lilly announced mirikizumab for treatment of ulcerative colitis met primary and secondary endpoints in the LUCENT-1 12-week, phase 3 induction study, according to a press release.

The intravenous and subcutaneous formulations of Remsima had comparable efficacy, safety and immunogenicity profiles in patients with inflammatory bowel disease, according to study results.

Patients with ulcerative colitis treated with Entyvio had a lower risk for serious infections compared with those who received anti-TNF, according to study results.

The FDA has issued a safety alert warning patients and health providers of an increased risk for serious health-related problems and cancer linked to tofacitinib compared with TNF inhibitors among older patients.